Latest Earnings Results: Q3 '26
Estimated EPS
$1.27
Reported EPS
$1.77
Surprise
+39.7%
Estimated Rev
$2.75B
Reported Rev
$2.94B
Surprise
+6.76%
• Reported GAAP EPS of $2.52 up 56.52% YoY • Reported revenue of $4.19B up 56.17% YoY • Bausch Health raised FY2026 guidance: consolidated revenue of $10.98B$11.18B and Adjusted EBITDA of $4.32B$4.42B; excluding Bausch + Lomb, revenue is $5.53B$5.63B, Adjusted EBITDA $3.23B$3.28B, and adjusted cash flows $1.6B$1.68B.
Bullish Takeaway
Bausch Health reported Salix and Bausch + Lomb organic growth, fourteen consecutive quarters of revenue and Adjusted EBITDA growth excluding Bausch + Lomb, and cash generation supporting more than $500M of net debt reduction.
Bearish Takeaway
Bausch Healths Solta Medical organic revenue and Diversified nine-month organic revenue decreased, including Generics and Dentistry; the filing cites negotiated Xifaxan prices and says tariff impacts may be adverse.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $1.35 | -- | -- | N/A |
Q3 '26 | $1.27 | $1.77 | 39.70% | BEAT |
Q2 '26 | $1.01 | $1.26 | 25.12% | BEAT |
Q1 '26 | $0.67 | $0.78 | 16.13% | BEAT |
Q4 '25 | $1.20 | $1.08 | -10.58% | MISSED |